IsoRay, Inc. (DE) (ISR) News

IsoRay, Inc. (DE) (ISR): $0.67

0.00 (0.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ISR News Items

ISR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ISR News Highlights

  • ISR's 30 day story count now stands at 13.
  • Over the past 9 days, the trend for ISR's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
  • BODY, SEED and WASH are the most mentioned tickers in articles about ISR.

Latest ISR News From Around the Web

Below are the latest news stories about Isoray Inc that investors may wish to consider to help them evaluate ISR as an investment opportunity.

American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131

RICHLAND, Wash., Sept. 28, 2021 (GLOBE NEWSWIRE) -- The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131 has been included in ABS’s highly respected consensus guidelines. Because Cesium-131 seeds were not available as a treatment until 2004, long-term outcomes following Cesium-131 prostate brachytherapy seeds have only recently

Yahoo | September 28, 2021

IsoRay Consensus Indicates Potential 233.8% Upside

IsoRay with ticker code (ISR) now have 3 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 3 and 1.6 calculating the mean target price we have 2.17. Now with the previous closing price of 0.65 this indicates there is a potential upside of 233.8%. The 50 day MA is 0.66 and the 200 day moving average is 0.84. The company has a market cap of $89m. Find out more information at: /> [stock_market_widget type="chart" symbol="ISR" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Isoray, through its subsidiary, IsoRay Medical, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company pro...

DirectorsTalk | September 23, 2021

IsoRay, Inc. (NYSEAMERICAN: ISR) Posts Inline Earnings for the Fourth Quarter of FY 21

IsoRay, Inc. (NYSEAMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, stock fell 3.06% (As on The post IsoRay, Inc. (NYSEAMERICAN: ISR) Posts Inline Earnings for the Fourth Quarter of FY 21 appeared first on FXDailyReport.Com .

FXDailyReport | September 22, 2021

Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2021 Financial Results

Record Full Year Revenue Fiscal Fourth Quarter Revenue Increased 19% Year-Over-Year

Intrado Digital Media | September 21, 2021

Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues

Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT

Intrado Digital Media | September 21, 2021

Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues

Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PTRICHLAND, Wash., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, will host a rescheduled conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2021 on Wednesday, September 22, 2021, at 10:00 a.m. Eastern Time/7:00 a.m. Pacific

Yahoo | September 21, 2021

IsoRay (ISR) Reports Q4 Loss, Tops Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 3.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | September 21, 2021

Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2021 Financial Results

Record Full Year RevenueFiscal Fourth Quarter Revenue Increased 19% Year-Over-Year RICHLAND, Wash., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced financial results for the fiscal fourth quarter and full-year ended June 30, 2021. Revenue for the fourth quarter of fiscal 2021 grew 19% to $2.71 million versus $2.28 million in the prior ye

Yahoo | September 21, 2021

IsoRay is about to announce earnings here''s what Wall Street expects

IsoRay releases figures for Q4 on September 21. Wall Street analysts expect IsoRay will be reporting losses per share of $0.010. Watch IsoRay stock price move in real-time ahead here. On September 21, IsoRay will present their

Business Insider Markets | September 19, 2021

Will IsoRay (ISR) Report Negative Q4 Earnings? What You Should Know

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | September 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.1075 seconds.